Outcome of Board Meeting held on May 25, 2026
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions reported audited FY2026 results with consolidated revenue of Rs 6,591 crore (up 29% YoY) and consolidated PAT of Rs 145.8 crore (up 36% YoY). The Board re-appointed three Independent Directors (Sujesh Vasudevan, Rajesh Dalal, and Sandhya Gadkari Sharma) for a second five-year term effective August 25, 2026, subject to shareholder approval. The company allotted 7,240 equity shares upon exercise of employee stock options and granted fresh 7,300 ESOPs. An acquisition of Vishal Surgicals and Vishal Surgicals & Medicals was approved through subsidiary Sai Pharma Distributors Private Limited via slump sale. The 8th AGM is scheduled for August 19, 2026. Statutory auditors MSKA & Associates gave an unmodified opinion.
Strong financial performance with revenue and profit growth reflects successful integration of recent acquisitions. The re-appointment of independent directors signals board stability and continuity of governance standards.